In Vitro & In Vivo Diagnostic Substances — Ranked by Total Assets
SIC 2835 · Annual figures from SEC 10-K filings
These rankings show the largest In Vitro & In Vivo Diagnostic Substances companies by total assets, based on the most recent fiscal year data reported in their annual 10-K filings with the SEC. Only companies with XBRL-tagged financial data are included. Use the tabs below to switch between revenue, net income, and total assets.
| # | Company | Total Assets | Fiscal Year |
|---|---|---|---|
| 1 | QuidelOrtho Corp QDEL | $5.77B | FY2025 |
| 2 | NEOGEN CORP NEOG | $3.44B | FY2025 |
| 3 | IDEXX LABORATORIES INC /DE IDXX | $3.35B | FY2025 |
| 4 | Lantheus Holdings, Inc. LNTH | $2.23B | FY2025 |
| 5 | Intellia Therapeutics, Inc. NTLA | $842.13M | FY2025 |
| 6 | MYRIAD GENETICS INC MYGN | $706.60M | FY2025 |
| 7 | Celldex Therapeutics, Inc. CLDX | $582.98M | FY2025 |
| 8 | Alpha Teknova, Inc. TKNO | $103.58M | FY2025 |
| 9 | IMMUCELL CORP /DE/ ICCC | $42.53M | FY2025 |
| 10 | ACHIEVE LIFE SCIENCES, INC. ACHV | $41.79M | FY2025 |
| 11 | Q/C TECHNOLOGIES, INC. QCLS | $41.17M | FY2025 |
| 12 | Insight Molecular Diagnostics Inc. IMDX | $25.76M | FY2025 |
| 13 | Cardio Diagnostics Holdings, Inc. CDIOW | $7.77M | FY2025 |
| 14 | VOLITIONRX LTD VNRX | $6.90M | FY2025 |
| 15 | BIOMERICA INC BMRA | $5.95M | FY2025 |
| 16 | Aspira Women's Health Inc. AWHL | $5.46M | FY2025 |
| 17 | BURZYNSKI RESEARCH INSTITUTE INC BZYR | $847 | FY2025 |